{
  "report_rows": [
    {
      "kpi": "Adjusted operating EPS",
      "prediction": "IN-LINE",
      "answer": "pred ~$3.64 vs. cons $3.61",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Skyrizi revenue",
      "prediction": "BEAT",
      "answer": "pred ~$5.510B vs. cons $5.443B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Neuroscience revenue",
      "prediction": "BEAT",
      "answer": "pred ~$3.150B vs. cons $3.116B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 adjusted EPS",
      "prediction": "UNCHANGED",
      "answer": "guide ~$13.91-$14.11 vs. cons $14.09",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 net revenue",
      "prediction": "UNCHANGED",
      "answer": "guide ~$67.3B vs. cons $67.38B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q3 2026 adjusted EPS",
      "prediction": "UNCHANGED",
      "answer": "guide ~$3.84-$3.88 vs. cons $3.85",
      "confidence": "LOW"
    },
    {
      "kpi": "FY 2026 Skyrizi demand tone",
      "prediction": "BETTER",
      "answer": "continued IBD/share-gain strength; consensus UNVERIFIED",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -1.5,
  "day1_confidence": "LOW",
  "day5_residual_pct": -2.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 implicit Q4 estimate risk",
  "day5_confidence": "LOW"
}